ADMA Biologics Inc Common Stock (ADMA)

FairStock Score: 57/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn high returns on capital and sell at a margin of safety. ADMA makes specialty plasma-derived biologics, with products like BIVIGAM and ASCENIV. It has turned around: in fiscal year 2023, the period ended 2023-12-31, revenue was $258.2M and net income was a loss of $28.2M, or diluted EPS of $-0.13. By fiscal year 2025, the period ended 2025-12-31, revenue reached $510.2M and net income was $146.9M, or $0.60 diluted EPS. That is real progress. But the latest quarter shows slower growth. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $124.4M and net income was $37.8M, or $0.16 diluted EPS. Compared with fiscal Q2 2025, the quarter ended 2025-06-30, revenue was $122.0M and net income was $34.2M, so revenue grew only about 1.98% while profit grew about 10.53%. Also, fiscal year 2025 net income of $146.9M and diluted EPS of $0.60 were below fiscal year 2024's $197.7M and $0.81, even as revenue rose from $426.5M to $510.2M. Financial health looks solid: FairStock calculates ROE of 41.90%, ROCE of 21.78%, D/E of 0.50, Altman Z of 6.09, and Piotroski F-score of 6/9. At the close on 2026-10-13, the price was $10.31. FairStock calculates P/E 14.73, P/B 5.70, EV/EBITDA 10.20, FCF yield 5.0%, and a Graham Number of $5.34, meaning the price is 93.07% above that conservative value. The P/E is not demanding, but P/B and negative margin of safety require continued high returns. FairStock labels it a TURNAROUND. I want more durable growth before calling it a bargain.

In plain English: ADMA Biologics makes specialty plasma-based medicines for immune deficiencies and infectious diseases. The business is profitable and generates cash, but sales barely grew in the latest reported quarter and the stock price is well above a conservative asset-value check. Overall, the business looks decent but not clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer